- Datum23.04.2024
- UhrzeitLäuft gerade
- Veranstalter
XTB
Rüdiger Born
Moderator
stock3 TerminalDu willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnen
Myriad Genetics Inc. Kurse
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
1,38 %
Intraday
-0,92 %
1 Woche
-15,71 %
1 Monat
-2,06 %
Seit Jahresbeginn
-16,58 %
1 Jahr
-37,72 %
3 Jahre
-42,23 %
5 Jahre
-52,76 %
10 Jahre
Wikifolio
Passender Service zu Myriad Genetics Inc.
Webinar zu Myriad Genetics Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)13,820-24,210
- Jahrestief / Hoch ($)17,180-23,750
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Myriad Genetics Inc.
Keine Dividenden verfügbar
Termine von Myriad Genetics Inc.
- Mai2Myriad Genetics Inc.Q1 2024 Earnings Release
- Aug1Myriad Genetics Inc.Q2 2024 Earnings Release
- Okt29Myriad Genetics Inc.Q3 2024 Earnings Release
Beschreibung
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
